Atezolizumab Does Not Improve Standard Care in HER2+ Early Breast Cancer - Cancer Therapy Advisor

Adding atezolizumab to standard neoadjuvant treatment did not increase the pathological complete response rate.

The addition of atezolizumab does not improve the efficacy of standard neoadjuvant treatment in patients with high-risk HER2-positive early breast cancer, a phase 3 trial suggests. In the IMpassion0… [+2998 chars]

full article...